AMTD Digital's Subsidiary TGE Announces Successful Completion of Acquisition of the New York Tribeca Hotel at US$69 Million

AMTD Digital's Subsidiary TGE Announces Successful Completion of Acquisition of the New York Tribeca Hotel at US$69 Million

PARIS, NEW YORK and LONDON, March 9, 2026 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), AMTD Digital Inc. (NYSE: HKD) and The Generation Essentials Group ("TGE", NYSE: TGE; LSE: TGE), a subsidiary of AMTD...

Zeekr Group Announces Completion of Merger

Zeekr Group Announces Completion of Merger

HANGZHOU, China, Dec. 22, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced the completion of its merger (the...

Bright Scholar Announces Completion of Going Private Transaction

Bright Scholar Announces Completion of Going Private Transaction

CAMBRIDGE, England and FOSHAN, China, Dec. 16, 2025 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") (NYSE: BEDU), a global premier education service company, today announced the completion of the merger...

Emeren Group Announces Completion of Merger

Emeren Group Announces Completion of Merger

NORWALK, Conn., Dec. 15, 2025 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced the completion of the merger contemplated by the...

State Grid Jinchang (Gansu): Realizing Direct Grid Supply to All Residential Communities

State Grid Jinchang (Gansu): Realizing Direct Grid Supply to All Residential Communities

JINCHANG, China, Nov. 27, 2025 /PRNewswire/ -- On November 18, with the completion of power supply renovation for the last 521 households in Phase II of Yongdian Huayuan Community in Hexibao Town, Yongchang County, Jinchang City, Gansu Province, all...

Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its...

Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026

Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026

COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a...

ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China

ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China

SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity...

BEST Inc. Announces Completion of Going Private Transaction

BEST Inc. Announces Completion of Going Private Transaction

HANGZHOU, China, March 8, 2025 /PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China and Southeast Asia, today announced the completion of its...

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab,...

  • 1
  • 2
  • menu
    menu